期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

促甲状腺激素受体抗体和甲状腺过氧化物酶抗体检测对Gravse病的诊断意义 被引量：4

原文传递
导出
摘要 目的探讨促甲状腺激素受体抗体(Thyrotropin Receptor Antibody,TRAb)和甲状腺过氧化物酶抗体(Thyroid Peroxidase Antibody,TPOAb)测定对格雷夫斯病(Gravse病,GD)的诊断价值。方法用放射受体分析法(Radio Receptor Assay,RRA)对75例初诊GD患者,99例未控制的GD患者,112例经抗甲状腺药物治疗缓解的GD患者,23例GD复发患者,56例健康体检者分别进行TRAb和TPOAb的测定。结果 GD初诊组、未控制组、复发组TRAb水平和阳性率均显著高于GD控制组(P<0.05),GD控制组TRAb水平和阳性率显著高于正常对照组(P<0.05),差异均有统计学意义。GD患者各组TPOAb水平和阳性率均显著高于正常对照组(P<0.05)。结论检测血清TRAb和TPOAb水平在GD发病、进展及复发具有重要的临床意义。
作者 曲莉 万晓艳 罗艳华
机构地区 北华大学公共卫生学院 吉林省地方病第二防治研究所
出处 《中国地方病防治》 2013年第6期429-430,共2页 Chinese Journal of Control of Endemic Diseases
关键词 Gravse病 促甲状腺激素受体抗体 甲状腺过氧化物酶抗体 放射受体分析法
分类号 R581.1 [医药卫生—内分泌]
  • 相关文献

参考文献8

  • 1马萍,刘宽芝,王战建,黄建敏.格雷夫斯病患者血清促甲状腺激素受体抗体检测的临床意义[J].临床荟萃,2010,25(17):1498-1500. 被引量：2
  • 2段东,倪济苍,罗加,邓红,陶林.检测血清TRAb水平在甲状腺疾病诊治中的价值[J].重庆医科大学学报,2004,29(3):342-344. 被引量：3
  • 3Anja Eckstein,Klaus Mann,George J. Kahaly,Martin Gru?endorf,Christoph Reiners,Joachim Feldkamp,Beate Quadbeck,Andreas Bockisch,Prof. Dr. Matthias Schott.Bedeutung der TSH-Rezeptor-Antik?rper für die Diagnose des Morbus Basedow sowie die Prognoseabsch?tzung der Schilddrüsenüberfunktion und der endokrinen Orbitopathie[J].Medizinische Klinik.2009(5)
  • 4Laurberg Peter,Wallin G?ran,Tallstedt Leif,Abraham-Nordling Mirna,Lundell G?ran,T?rring Ove.TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study[].European journal of endocrinology / European Federation of Endocrine Societies.2008
  • 5Watanabe Y,Tahara K,Hirai A,Tada H,Kohn L D,Amino N.Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild-type or chimeric human TSH receptor[].Thyroid : official journal of the American Thyroid Association.1997
  • 6Heufelder A E.Pathogenesis of Graves’ ophthalmopathy: recent controversies and progress[].European journal of endocrinology / European Federation of Endocrine Societies.1995
  • 7Arao T,Morimoto I,Kakinuma A,et al.Thyrocyte proliferation by cellular adhesion to infiltrating lymphocytes through the intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 pathway in Graves’ disease[].Journal of Clinical Endocrinology and Metabolism.2000
  • 8Ghoraishian SM,Hermetic Moghaddam SH,Aikhamr Ardekani M.Relationship between anti - thyroids peroxides antibody and thyroid function test[].Iran J Immunol.2006

二级参考文献13

  • 1刘超,张忠邦.甲状腺特异性抗体[J].中华内分泌代谢杂志,1994,10(1):28-30. 被引量：31
  • 2薛晓英,张力辉,刘会芝,李彦格,李渡斌,刘志和.放疗治疗甲亢性突眼病的疗效观察及其与甲状腺刺激性抗体的关系[J].临床荟萃,2005,20(13):740-743. 被引量：1
  • 3Aleksic A,Aleksic Z, Stojanovic M. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration,in newly diagnosed Graves" disease patients[J]. Hell J Nucl Med, 2009,12(2) :146-150.
  • 4Nedrebo BG, Holm PI, Uhlving S, et al. Predictors of outcome and comparison of different drug regimens for the prevetion of relapse in patients with Graves" diease[J]. Eur J Endocrinol, 2002,147(5) :583-589.
  • 5Wallaschofski H, Miehle K, Mayer A, et al. Prediction of remission or relapse for Graves" hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawl of antithyroid drug treatrnent[J]. Horm Metab Res,2002,34(7):383-388.
  • 6Bahn RS, Dutton CM, Natt N, et al. Thyrotropin recepter expression in Graves' orbital adipose/connective tissue:potential autoantigen in Graves' ophthalmopathy[J].J Clin Endocrinol Metab, 1998,83 (3) : 998-1002.
  • 7Butch HB,Sellitti D,Banes SG,et al.Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocularflbroblasts obtained from patients with Grave' Sophthalmopathy [ J ].J Clin Endoerinol Metab,1994; 78 (6):1384.
  • 8高妍.Graves病诊治中的几个问题[J].中华内分泌代谢杂志,2001,17(4):193-194. 被引量：71
  • 9蒋乐堂,杨建华,梅云风,胡伟.TRAb、TPOAb联检在甲状腺疾病诊治中的应用价值[J].中国实用内科杂志,2001,21(9):540-541. 被引量：10
  • 10徐琴芳,朱燕.血清TRAb检测在Graves甲亢治疗中的意义[J].放射免疫学杂志,2001,14(6):328-330. 被引量：13

共引文献3

同被引文献33

  • 1宋武战,池君,汪静.促甲状腺激素受体抗体(TRAb)测定的临床价值[J].放射免疫学杂志,2007,20(5):399-401. 被引量：33
  • 2中华医学会核医学分会.^131Ⅰ治疗格雷夫斯甲亢指南(2013版).中华核医学与分子影像杂志,2013,4:83-95.
  • 3Jukic T, Stanicic J, Petric V, et al. Radioiodine versus surgery in the treatment of Graves' hyperthyroidism. Lijec Vjesn, 2010, 132 ( 11- 12) :355-360.
  • 4Bojarska S A, Janicki K, Pietura R, et al. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow' s disease. Ann Univ Marise Curie Sklodowska Med ,2003,58 ( 1 ) :248-253.
  • 5Aleksic A Z, Aleksid A Z P, Mitov V M, et al. Reliability of the thyroid stimulating hormone receptor antibodies level determination in diagnosing and prognosing of autoimmune hyperthyroidism. VojnosanitPregl, 2009,66 (10) : 779-784.
  • 6Hautzel H, Pisar E, Yazdan-Doust N, et al. Qualitative and quantitative impact of protective glucocorticoid therapy on the effectivel31I half-life in radioiodine therapy for Graves' disease . J Nucl Med. 2010,51 (12) :1917-1922.
  • 7Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease. J Clin Endocrin Metab, 2007,92(9) :3547-3552.
  • 8van Isselt J W, Broekhuizen-de Gast H S. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease. Hell J Nucl Med,2010,13( 1 ) :2-5.
  • 9唐大东.不同方法治疗Graves病的疗效观察[J].中外医疗,2010,29(7):14-15. 被引量：4
  • 10朱利国,浦洪波,武红玉,李跃松,陈永伟.促甲状腺激素、甲状腺过氧化物酶抗体和促甲状腺激素受体抗体检测在甲状腺疾病中的应用价值[J].标记免疫分析与临床,2010,17(4):241-243. 被引量：20

引证文献4

二级引证文献45

中国地方病防治
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部